Proactive Investors CEO Interview – Algernon NeuroScience Doses First Patient in Stroke Study

Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news that the Company has announced its subsidiary, Algernon NeuroScience, has dosed the first subject in the Phase 1 DMT clinical stroke study. Algernon is the very first company in the world to investigate DMT for stroke.

Mr. Moreau explains that the dosing took place in the Netherlands where the study is being conducted at the Centre for Human Drug Research in Leiden. This study is to use a single-escalating dose design aimed at identifying a safe and tolerable dose that will not produce psychedelic effects.

Phase 2 acute stroke and rehabilitation studies are expected to commence in stroke patients by the end of 2023.